“Chevron Corporation and Texas Children’s Hospital [on Thursday] announced a $6 million, five-year agreement to expand the hospital’s Global Health Corps program that provides life-saving pediatric health care, treatment, and training to the most medically underserved populations in Africa,” a Chevron press release states. “Chevron’s contribution will support the recruitment and…
Private Sector Involvement
In this post in the Health Affairs blog, Martha Kwataine, executive director for the Malawi Health Equity Network (MHEN) and head of the Access to Medicines Campaign in Malawi, examines the role of local advocates and non-governmental organizations (NGOs) in the country’s health system. She writes, “Amidst [Malawi’s health] challenges, the role of civil society, especially advocates, cannot be overemphasized. Civil society organizations are the ‘watchdogs’ of government. Historically, they have played a critical role, not just by influencing policy formulation, but also by providing checks and balances to government power.”
In this post in the Hill’s “Congress Blog,” John Castellani, president and CEO of Pharmaceutical Research and Manufacturers of America, reports on how biopharmaceutical exports benefit the U.S. economy and global health, writing, “Leadership is needed to help keep U.S. biopharmaceutical research companies competitive in the global export market.” He continues, “According to the Administration, if we increased exports by just five percent, we would create hundreds of thousands of new U.S. jobs. … Among the ways that they can advance this effort is by knocking down foreign barriers and promoting strong intellectual property (IP) protections that allow biopharmaceutical companies to bring their medicines into other markets and, importantly, to the patients who need them.”
In this Africa.com opinion piece, Ana Ruth Luis, medical director of the Southern Africa Strategic Business Unit at Chevron Africa and Latin America Ex in Angola, discusses what she calls “the important role Chevron has in driving down the incidence of HIV/AIDS in Africa.” She writes, “Chevron was able to drop new infections to zero among our employees and their babies by educating our employees, establishing a culture of voluntary, confidential testing and treatment, addressing stigma and discrimination in the workplace, and providing comprehensive medical care for expectant mothers.”
In this post in the Hill’s “Congress Blog,” Kaitlin Christenson, the coalition director of the Global Health Technologies Coalition; Jim Connolly, president and CEO of Aeras; and Mel Spigelman, president and CEO of the TB Alliance, respond to a recently released G-FINDER report that shows “overall global investment in the research and development (R&D) of [new global health technologies] has declined for the first time since 2007, when the tracking of such funding began,” writing, “This decline is especially troubling given that there are more than 100 products in [the Product Development Partnerships’ (PDPs)] pipelines.”
“A group of health organizations [on Wednesday] launched a new international consortium to better prepare the clinical research community to respond to the next pandemic or other emerging health threat,” CIDRAP News reports (Schnirring, 12/7). “The International Severe Acute Respiratory Infection Consortium (ISARIC) is a global collaboration of over 20 hospital-based clinical research networks … aimed at ensuring the clinical researchers have in place the necessary open access protocols and data-sharing processes and have considered the ethical issues that will allow them to respond to rapidly emerging diseases with epidemic or pandemic potential, such as the recent pandemic H1N1 influenza and SARS outbreaks and potentially other rapidly emerging public health threats,” according to a Wellcome Trust press release.
Pharmaceutical company Merck (MSD) announced Monday it has “awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings,” according to a Merck press release. Led by scientists from Merck for Mothers,…
“The public and private sectors have achieved remarkable success in Africa in the battle against AIDS, and the question now is: Where do we go from here?” James Glassman, founding executive director of the George W. Bush Institute and former under secretary of state for public affairs and public diplomacy, writes in this Forbes opinion piece. Noting the “incredible accomplishment” made in fighting HIV/AIDS over the past decade, Glassman says “the first answer to where we go from here is more of the same, and then some,” and states that the UNAIDS targets of “Zero new HIV infections” and “Zero AIDS-related deaths” “soun[d] right.”
“If the momentum gained in the last few years” in fighting global diseases such as HIV, tuberculosis (TB), malaria, measles, and meningitis “is any indicator of our future trajectory, we are standing on the threshold of a revolutionary change in the state of global health,” Wendy Taylor, senior adviser of Innovative Finance and Public Private Partnerships at USAID, and David Cook, executive vice president and COO of the International AIDS Vaccine Initiative (IAVI), write in this opinion piece in The Hill’s “Congress Blog.” They discuss the importance of “Product Development Partnerships, or PDPs for short,” which “are great examples of public-private collaborations [that] are starting to build deep pipelines for new drugs, vaccines, and diagnostic tools.”
“China’s vaccine makers are gearing up over the next few years to push exports in a move that should lower costs of lifesaving immunizations for the world’s poor and provide major new competition for the big Western pharmaceutical companies,” the Associated Press reports in a feature examining the entry of Chinese vaccine makers into the international market. “China’s entry into this field is important because one child dies every 20 seconds from vaccine-preventable diseases each year,” the news agency writes, adding that the country’s “vaccine makers, some of whom already export in small amounts, are confident they will soon become big players in the field” (Wong, 11/29).